Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Mivebresib |
| Synonyms | |
| Therapy Description |
ABBV-075 (Mivebresib) is a bromodomain (BET) inhibitor, which may inhibit Ar and Myc downstream signalling to prevent growth and proliferation of tumor cells (PMID: 30647404). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Mivebresib | ABBV-075 | BET Inhibitor (Pan) 30 | Mivebresib (ABBV-075) is a bromodomain (BET) inhibitor, which may disrupt transcriptional regulation and lead to apaotosis of tumor cells (PMID: 28416490, PMID: 31420359). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| Unknown unknown | acute myeloid leukemia | not applicable | Mivebresib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Mivebresib (ABBV-075) induced apoptosis and inhibited growth of acute myeloid leukemia (AML) cell lines and patient-derived cells in culture, and inhibited tumor growth in an AML cell line xenograft model (PMID: 28416490). | 28416490 |
| Unknown unknown | multiple myeloma | not applicable | Mivebresib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with Mivebresib (ABBV-075) altered expression of ZCCHC24, HEXIM1, SERPINI1, and MYC in a multiple myeloma cell line in culture and in xenograft models, and these changes correlated with inhibition of proliferation in culture and inhibition of tumor growth in xenograft models (PMID: 27903752). | 27903752 |
| Unknown unknown | Advanced Solid Tumor | not applicable | Mivebresib | Phase I | Actionable | In a Phase I trial, Mivebresib (ABBV-075) treatment demonstrated safety and modest clinical activity, resulted in stable disease as best response in 43% (26/61) of evaluable patients with advanced solid tumors, with a median progression-free survival of 1.8 months (PMID: 31420359; NCT02391480) . | 31420359 |
| Unknown unknown | uveal melanoma | not applicable | Mivebresib | Phase I | Actionable | In a Phase I trial, Mivebresib (ABBV-075) treatment demonstrated safety and modest clinical activity in patients with uveal melanoma, resulting in stable disease as best response in 44% (4/9) of evaluable patients, patients achieved stable disease had lower cfDNA mutational load of pathogenic mutations (53.1 vs 893.9 median mutant molecules/mL plasma) compared to patients developed progressive disease (J Clin Oncol 37, no. 15_suppl; NCT02391480). | detail... |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04480086 | Phase I | Mivebresib + Navitoclax Mivebresib + Ruxolitinib Mivebresib | Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | Recruiting | USA | 11 |
| NCT02391480 | Phase I | Mivebresib | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | Completed | USA | 0 |
CKB BOOST